AstraZeneca
1,801.00 SEK
-2.81 %
Less than 1K followers
AZN
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-2.81 %
+4.13 %
+8.56 %
+5.72 %
+13.27 %
+38.33 %
+16.95 %
+104.13 %
+9,754.72 %
AstraZeneca is a global pharmaceutical company focused on the research, development and marketing of prescription medicines, primarily for the treatment of diseases in the therapeutic areas of respiratory, cardiovascular/metabolic and cancer. In addition to its core business, the company also has a focus on the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in all global regions and is headquartered in Cambridge, UK.
Read moreMarket cap
2.79T SEK
Turnover
554.66M SEK
Revenue
540.24B
EBIT %
23.4 %
P/E
29.67
Dividend yield-%
1.63 %
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
29/4
2026
Interim report Q1'26
27/7
2026
Interim report Q2'26
All
Press releases
ShowingAll content types
AstraZeneca: Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
AstraZeneca: Alexion data at 2026 AAN Annual Meeting reflects industry-leading portfolio and commitment to enhancing care across rare diseases
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools